Metabolomics in urogenital cancer

Although in recent decades the development of many drugs against cancer has been witnessed, the morbidity and mortality for the most prevalent urogenital cancer have not been significantly reduced. A key task in cancer medicine is to detect the disease as early as possible. In order to achieve this, many new technologies have been developed for cancer biomarker discovery. Monitoring fluctuations of certain metabolite levels in body fluids, such as urine, has become an important way to detect early stages in carcinogenesis. Moreover metabolomic approaches are likely to be used to screen for potential diagnostic and prognostic biomarkers of urogenital...

To view this content, please register now for access

It's completely free